More on Amgen (AMGN): Q4 misses slightly on a per share basis due to higher sales costs, but...

|About: Amgen Inc. (AMGN)|By:, SA News Editor

More on Amgen (AMGN): Q4 misses slightly on a per share basis due to higher sales costs, but beats on revenue. Overall sales growth was positive, with strong performance coming from its two heavyweight drugs, Xgeva and Prolia, plus decent showings as well from Neupogen and Neulasta. The Company expects FY12 revenue in the range of $16.1B - $16.5B. Shares +0.8% AH.